
Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited’s filing records Lesley Russell’s cessation as a director on 11 November 2026. The notice identifies Russell as the registered holder
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IUGNF | Imugene | 0.03 | -0.17 | -85.64% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.03 | -85.64% |

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited’s filing records Lesley Russell’s cessation as a director on 11 November 2026. The notice identifies Russell as the registered holder

Imugene ( ($AU:IMU) ) just unveiled an update. Imugene is a clinical-stage immuno-oncology and cell therapy company developing an allogeneic, off-the-shelf CAR T product, azer-cel, which targets CD19 to treat

An announcement from Imugene ( ($AU:IMU) ) is now available. Imugene said Dr Lesley Russell resigned as a non-executive director effective immediately after the company’s 11 November 2026 annual general

The latest announcement is out from Imugene ( ($AU:IMU) ). Imugene is a clinical-stage cell therapy company developing an allogeneic CAR T for blood cancers. Its lead asset is azer-cel

The latest announcement is out from Imugene ( ($AU:IMU) ). Imugene is a clinical-stage immuno-oncology company developing allogeneic CAR T-cell therapies for blood cancers. Its lead product, azer-cel, is an

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene has agreed with CVI Investments to amend terms of its existing convertible notes issued in December 2025 and August 2026. The

Imugene ( ($AU:IMU) ) has shared an announcement. Imugene reported strong clinical progress for its azer-cel Phase 1b program, with the BTKi Combination Cohort achieving an overall response rate of

An announcement from Imugene ( ($AU:IMU) ) is now available. Imugene has reported new efficacy data from its ongoing Phase 1b basket trial of its CAR T candidate azer-cel in

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has applied for quotation on the ASX of 670,719 ordinary fully paid shares, to be issued on August 3, 2026.

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene Limited has called its 2026 Annual General Meeting for 11 November in Sydney and online, outlining a broad agenda that includes
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | May 28, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 3, 2027TBA | $12.19M | $-0.02 | $0.00 | 0.00 | -0.10 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.